From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Why FTSE 100 stocks such as GSK and Vodafone are always worth thinking about (but only one of them is a buy today)

By Chris Bailey | Wednesday 1 February 2023


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Many, many years ago, I remember somebody saying to me that investing in FTSE 100 stocks was pointless as “everything is priced in very efficiently”. What utter rubbish (as I told them at the time). Whilst the world of large cap stocks is covered by more analysts and mentioned more frequently by the press and financial TV, there are still plenty of opportunities to materially beat the index. And that is why today’s updates from both Vodafone (VOD) and (the previously named GlaxoSmithKline) GSK plc (GSK) are worth (at least) thinking about.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 21:43:43